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Protein engineering is a powerful tool for modification of the
structural, catalytic, and binding properties of natural proteins and
for the de novo design of artificial proteins. Although amino acid
replacement is normally limited to the 20 proteinogenic amino acids,
it is becoming increasingly clear that incorporation of non-natural
amino acids can extend the scope and impact of protein engineering
methods.1
We have previously exploited the ability of auxotrophic Es-
cherichia coli strains to effect efficient incorporation of amino acid
analogues into proteins in a multisite fashion. The method is simple
and produces high protein yields, and incorporation of the analogue
at multiple sites offers significant advantages with respect to control
of protein properties such as thermal and chemical stability.2
In this study, we report a computationally designed variant of
the E. coli phenylalanyl-tRNA synthetase (ePheRS), which allows
efficient in vivo incorporation of aryl ketone functionality into
proteins. In 1991, Kast and co-workers3 introduced a variant of
ePheRS (termed ePheRS*), which bears an Ala294Gly mutation
in the R-subunit and which thereby acquires relaxed substrate
specificity. We have recently shown that overexpression of ePheRS*
can be exploited to effect efficient incorporation of p-bromo-,
p-iodo-, p-ethynyl-, p-cyano-, and p-azidophenylalanines into
recombinant proteins in E. coli hosts.4,5 But similar experiments
with p-acetylphenylalanine (2) failed; even in a host in which
ePheRS* was overexpressed, phe-depleted cultures supplemented
with 2 did not produce substantial yields of protein (Figure 1).
Our interest in 2 arises from the chemical versatility of the side-
chain ketone function, which can be chemoselectively ligated with
hydrazide, hydroxylamino, and thiosemicarbazide reagents under
physiological conditions.6,7 Cornish and co-workers have ac-
complished site-specific incorporation of ketone functionality into
recombinant proteins via in vitro translation;8 however, we are
unaware of previous reports of in vivo methods of introducing
ketone functionality into recombinant proteins.
We sought ePheRS mutants that would allow efficient incorpora-
tion of 2 into recombinant proteins in vivo. The crystal structure
of Thermus thermophilus PheRS (tPheRS) complexed with 1 is
available9 and there is 43% overall sequence identity between
ePheRS and tPheRS; sequence identity in the identified active site
region is 80%. We therefore employed a previously described
protein design algorithm10 to identify potentially useful mutants of
tPheRS, with the intention to prepare and evaluate the corresponding
mutant forms of ePheRS. We generated a backbone-independent
rotamer library for 2, in which both the ł1 and ł2 torsional angles
were varied by (20° (in increments of 5°) from the values of 1 in
the tPheRS structure. Design calculations were performed by fixing
the identity of the substrate (2) and by allowing each of 11 non-
anchor sites in the amino acid binding pocket of tPheRS (determined
from the crystal structure) to be occupied by any of the 20 natural
amino acids except for proline, methionine, and cysteine. The
anchor residues (Glu128, Glu130, Trp149, His178, Ser180, Gln183,
and Arg204) were held fixed in identity and conformation in all
calculations. These residues contribute important electrostatic
interactions with the substrate and it is reasonable to assume that
such interactions are equally critical for the binding of 2.
The calculations identified two important cavity-forming muta-
tions: Val261 (Thr251 in E. coli) to Gly, and Ala314 (Ala294 in
E. coli) to Gly. These predictions are consistent with the results of
Reshetnikova and co-workers,9 who pointed out that Ala314 and
Val261 hinder the binding of amino acids larger than phe (e.g.,
tyrosine) into the active site of tPheRS. Further confidence in the
prediction was engendered by the fact that the Ala294Gly mutant
allows incorporation of an interesting set of para-substituted
phenylalanines, as described earlier.4,5 We were thus encouraged
to test whether the additional Thr251Gly mutation would relax the
specificity of ePheRS* sufficiently to allow incorporation of 2 into
proteins in vivo.
E. coli pheS* (which encodes ePheRS*) was amplified by the
polymerase chain reaction (PCR) from vector pQE-FS.4 Amplified
pheS* was subjected to PCR mutagenesis to create the coding
sequence for the desired Thr251Gly mutant, which we designate
pheS**. To allow constitutive expression of the synthetase, a tac
promoter with an abolished lac repressor binding site was inserted
upstream of the start codon of pheS**.11 The expression cassette
was then cloned into pQE15 (Qiagen), which encodes the marker
protein mouse dihydrofolate reductase (mDHFR). The resulting
plasmid was designated pQE-FS**. As a control, plasmid pQE-
FS* (which contained pheS* under control of a constitutive tac
promoter) was constructed similarly. AF-IQ, a phenylalanine* Corresponding author. E-mail: tirrell@caltech.edu.
Figure 1. SDS-PAGE of cell lysates of 4 h post-induction with 1 mM
IPTG. Expression plasmids and amino acid supplements are indicated. The
concentration of 1 is 20 mg/L and that of 2 is 250 mg/L. Lane M: molecular
weight marker (36.5, 31, 21.5, 14.4 kDa).
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auxotrophic E. coli strain carrying the repressor plasmid pLysS-
IQ,4 was transformed with pQE15, pQE-FS*, or pQE-FS** to
generate expression systems AF-IQ[pQE15], AF-IQ[pQE-FS*], and
AF-IQ[pQE-FS**], respectively. The capacity of 2 to support pro-
tein synthesis in each expression system was determined by induc-
tion of mDHFR expression in phenylalanine-free minimal media
supplemented with 2. As shown in SDS-PAGE analysis of whole
cell lysates (Figure 1), neither AF-IQ[pQE15] nor AF-IQ[pQE-
FS*] exhibits protein expression above background (-phe) in media
supplemented with 2.12 In contrast, similarly supplemented cultures
of AF-IQ[pQE-FS**] yield high levels of mDHFR expression. The
histidine-tagged protein from the latter culture (mDHFR-2) was
purified in a yield of about 20 mg/L, approximately 60% of that
obtained from cultures supplemented with 1. MALDI-TOF mass
spectrometry showed that the mass of mDHFR-2 was increased
by 304 Da, which corresponds to approximately 80% replacement
of 1 by 2 (mDHFR contains 9 phe residues). Incorporation of 2
was confirmed by tryptic digestion of mDHFR-2 (Figure 2). For
mDHFR, two peptides in the mass range 1550-1750 Da were
assigned to residues 34-47 and 93-106, respectively (Figure 2a).
Each fragment contains a single phe residue. The corresponding
fragments of mDHFR-2 (Figure 2b) were shifted up in mass by 42
Da, consistent with the increased mass of 2 relative to 1.13
We have completed preliminary studies of the reactivity of
mDHFR-2 toward hydrazide reagents. Purified mDHFR and
mDHFR-2 were dissolved in PBS buffer (pH 6.0) and treated either
with 5 mM biotin hydrazide (BH) or with PBS buffer as a negative
control. The reaction products were analyzed by western blotting
and visualized by treatment with a biotin-specific streptavidin-HRP
conjugate (Figure 3). The products were also examined for the
presence of the 6His tag of mDHFR to ensure the identity of the
protein band and to probe the possibility of chain cleavage under
the ligation conditions. The results are consistent with chemo-
selective ligation without chain cleavage (Figure 3b).
In conclusion, we describe here a new mutant form of the E.
coli phenylalanyl-tRNA synthetase, which allows efficient in vivo
incorporation of reactive aryl ketone functionality into recombinant
proteins. This study also demonstrates the power of computational
protein design in the development of aminoacyl-tRNA synthetases
for activation and charging of non-natural amino acids.
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Figure 2. MALDI TOF mass spectra of tryptic peptides digested from
mDHFR expressed in media supplemented with 1 (a) or 2 (b).
Figure 3. Western blot showing chemoselective modification of ketone
functionality in mDHFR. (a) Modified protein was treated with biotin
hydrazide (BH), stained with HRP conjugated streptavidin, and analyzed
by western blot. (b) Western blot analysis of the products. Lane 1: mDHFR-
wt + buffer. Lane 2: mDHFR-2 + buffer. Lane 3: mDHFR-wt + BH.
Lane 4: mDHFR-2 + BH.
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